Opinion

Video

Targeting Disease Modification in Psoriasis and Psoriatic Arthritis

Author(s):

Saakshi Khattri, MD,Jennifer Soung, MD

Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.

0:00 Overlap of PsO and PsA
4:00 Detecting Early PsA
13:20 Treatments for PsA
18:00 Defining Minimal Disease Activity
24:50 Biologics for PsA
31:00 Efficacy of IL-17i and IL-23i
37:00 Preventing Progression from PsO to PsA

Related Videos
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Melodie Young, ASN, RN: Updates on Therapies for Pediatric Patients with Psoriasis, PsA
Harnessing Patient Insights: The Role of PROs in Managing Psoriasis and Psoriatic Arthritis
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Related Content
FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA
December 2nd 2024

FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA

Victoria Johnson
MEDCast Podcast logo
October 1st 2024

Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Lauren Miller, MPAS, PA-C Jayme M Heim, MSN, FNP-BC Kirk Gautier, PA-C
Lihi Eder, MD, associate professor of medicine, Women’s College Hospital and University of Toronto, Canada
November 26th 2024

Guselkumab Similarly Efficacious Among Male, Female Patients With PsA

Victoria Johnson
MEDcast logo
August 1st 2024

Optimizing Treatment Outcomes in Retinal Vein Occlusion

Hong-Uyen Hua, MD Sruthi Arepalli, MD Geeta Lalwani, MD
Bimekizumab Maintains Efficacy for PsA Up to 2 Years Among Week 16 Responders
November 25th 2024

Bimekizumab Maintains Efficacy for PsA Up to 2 Years Among Week 16 Responders

Tim Smith
Diane Lacaille, MDCM, MHSc, Scientific Director and Senior Scientist at Arthritis Research Canada and Professor, Department of Medicine, University of British Columbia, Vancouver.
November 15th 2024

Glucocorticosteroid Use for Rheumatoid Arthritis Increases CVD, Infection Mortality Risk Even After Cessation

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.